HRT Financial’s Cymabay Therapeutics CBAY Stock Holding History

HRT Financial’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-385,676	Closed	-$3.36M	–	3523
2023 Q1	$3.36M	Buy	385,676 +311,482	+420%	+$2.49M	0.04%	387
2022 Q4	$465K	Buy	+74,194	New	+$282K	0.01%	1479
2021 Q4	–	Sell	-51,853	Closed	-$189K	–	4313
2021 Q3	$189K	Buy	+51,853	New	+$204K	﹤0.01%	2714
2021 Q1	–	Sell	-104,393	Closed	-$599K	–	3279
2020 Q4	$599K	Buy	+104,393	New	+$790K	0.01%	928
2020 Q3	–	Sell	-13,864	Closed	-$48K	–	2479
2020 Q2	$48K	Buy	+13,864	New	+$40K	﹤0.01%	1318
2019 Q4	–	Sell	-22,633	Closed	-$115K	–	1771
2019 Q3	$115K	Buy	+22,633	New	+$137K	0.01%	1232
2018 Q4	–	Sell	-24,709	Closed	-$273K	–	781
2018 Q3	$273K	Buy	+24,709	New	+$307K	0.04%	267

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

HRT Financial's CBAY Position: Q2 2023 in Review

HRT Financial sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 385,676 shares — an estimated $3.36M sold.

HRT Financial first reported a position in CBAY in Q3 2018 and held it in 7 quarters. The position peaked at $3.36M in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

HRT Financial reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 385,676 Cymabay Therapeutics shares in Q2 2023, an estimated $3.36M.
HRT Financial first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 7 quarters.
HRT Financial's Cymabay Therapeutics position peaked at $3.36M in Q1 2023.
151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.